Canadian Natural Resources on Friday forecast a modest rise in production for 2026 while lowering total capital spending from this year's levels, signaling a continued focus on efficiency and disciplined growth.

WALNUT CREEK, Calif.--(BUSINESS WIRE)---- $CENT #CentralToHome--Central Garden & Pet Company (NASDAQ: CENT), (NASDAQ: CENTA), a leading company in the pet and garden industries, today announced the opening of a state-of-the-art fulfillment center in Salt Lake City, Utah earlier this week. This strategic investment expands Central's supply chain network and supports continued long-term growth. The Salt Lake City facility consolidates two legacy sites — one in Ontario, California and one in Salt Lake City, Utah — int.

Constellation Energy Corporation (CEG) came out with quarterly earnings of $3.04 per share, missing the Zacks Consensus Estimate of $3.13 per share. This compares to earnings of $2.74 per share a year ago.

Preclinical data support best-in-class potential of masked T cell engager programs and platform utilizing Xilio's ATACR and SEECR formats, including efficient masking, potent anti-tumor activity and broad therapeutic index Phase 1 data for efarindodekin alfa, a tumor-activated IL-12, demonstrated promising monotherapy anti-tumor activity in patients with advanced solid tumors and generally well-tolerated safety profile Phase 2 data for vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4, show potential for ctDNA as an early predictor for response to treatment with vilastobart in combination with atezolizumab in patients with MSS mCRC WALTHAM, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a …

CALABASAS, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing novel brain-penetrant therapeutics for patients with malignant brain tumors and central nervous system (CNS) disorders, today announced that it will host an investor conference call and webcast on Wednesday, November 12, 2025, at 6:00 a.m. Pacific Time / 9:00 a.m. Eastern Time (prior to market open).

– CHS-114 demonstrated robust and selective depletion of CCR8+ Tregs as well as favorable immune remodeling in tumor tissue from head and neck squamous cell carcinoma (HNSCC) patients –

Pre-clinical data for IO Biotech's next T-win vaccine candidate, IO112 targeting arginase 1, demonstrates anti-tumor activity with dynamic changes in the tumor microenvironment (TME) driven by the vaccine-targeted modulation of immunosuppressive myeloid cells, including tumor-associated macrophages (TAMs) Pre-clinical data for IO Biotech's additional T-win vaccine candidate, IO170 targeting Transforming Growth Factor (TGF)-β, demonstrates induction of immune responses that could inhibit tumor growth and reduce lung metastasis Data presented at the Society for Immunotherapy of Cancer's Annual Meeting NEW YORK, Nov. 07, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, …

PALO ALTO, Calif.--(BUSINESS WIRE)--Intapp DealCloud was named Deal Origination solution of the Year: Credit at the 2025 Private Equity Wire U.S. Awards.

— Mec-V demonstrates median OS of 21.5 months in patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma compared with approximately 12 months with approved agents

NEW YORK, Nov. 07, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to reconstitute immunity to treat cancer and immune disorders, today announced updated clinical results evaluating agenT-797, alone and in combination with anti-PD-1 therapy, in patients with advanced solid tumors refractory to all approved treatments presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025 (Late Breaking Abstract #1344).

Novel INDUCER™ T Cell Engager Platform designed to mitigate systemic toxicities Sequential dosing of INDUKINE™ molecules in preclinical model showed potent antitumor activity with improved safety First-in-kind real-time pharmacokinetic data in a mouse tumor model confirmed WTX-124 selective activation in tumors, sparing healthy tissue WATERTOWN, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today shared preclinical data at the 2025 Society for Immunotherapy of Cancer's …

GARDNER, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced the receipt of a product development order to build sub-assemblies that will support an advanced augmented reality (AR) system for US Air Force fighter pilot training, powered by POC's next-generation optical sub-assembly design and manufacturing technologies.

Transfers listing to the Nasdaq Capital Market NAPLES, FL / ACCESS Newswire / November 7, 2025 / Rain Enhancement Technologies Holdco, Inc. (the "Company") (Nasdaq:RAIN, RAINW), today announced that it has regained compliance with the continued listing requirements of Nasdaq and has transferred the listing of its securities from the Nasdaq Global Market to the Nasdaq Capital Market. As previously announced, the Company was previously non-compliant with two requirements for continued listing on the Nasdaq Global Market: the requirement to maintain a market value of listed securities of at least $50 million and the requirement to maintain a market value …

Partnership built to scale growing policy market and public demand to address future-state concerns around humanoid and robotic systems, recognizing ethical and operational demands and risks to help ensure non-lethal innovation Partnership built to scale growing policy market and public demand to address future-state concerns around humanoid and robotic systems, recognizing ethical and operational demands and risks to help ensure non-lethal innovation

EMERYVILLE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will present at the Jefferies Global Healthcare Conference in London, November 17–20, 2025.

HOUSTON--(BUSINESS WIRE)--SISCO Holdings, LLC, a Delaware company wholly owned by Stewart Information Services Corporation (NYSE:STC) today announced its entry into an agreement to acquire the mortgage services of Mortgage Contracting Services (MCS), a property preservation services provider. As part of the agreement, Stewart will acquire all the operations and technology supporting mortgage servicers and lenders in their property preservation efforts. “We are pleased to announce our intent to.

Saskatoon, SK, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO; CSE: DPRO; FSE: 3U8A), an award-winning, industry-leading developer of drone solutions and systems, announced today that it will host a shareholder update call on November 12, 2025, at 5:30 PM EST.

SYDNEY & CHICAGO--(BUSINESS WIRE)--James Hardie Industries plc (NYSE/ASX: JHX) ("James Hardie" or the "Company"), a leading provider of exterior home and outdoor living solutions, today announced its participation at upcoming investor conferences hosted by UBS and Bernstein in December. The company also announced it will release financial results for the second quarter of its 2026 fiscal year before the market opens in the United States on Tuesday, November 18th. Conference Participation Detail.

SITC abstracts highlight updated immunogenicity results from the Phase 2 AMPLIFY-7P trial of ELI-002 7P and preclinical data on the use of intratumoral ELI-004 (AMP-CpG) for solid tumor immunotherapy ELI-002 7P induced mKRAS-specific T cell responses in 99% of evaluable patients (89/90), demonstrating potent and consistent immune activation Robust immune responses were elicited across all seven mKRAS antigens, with >80% response rate to each individual KRAS mutation and 88% of patients generating responses to their own tumor-specific mutation 86.8% (66/76) of patients induced cytotoxic mKRAS-specific T cell responses; 75% (57/76) induced CD8 + T cells and 75% (57/76) induced CD4 …

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the Jefferies 2025 London Healthcare Conference on Tuesday, November 18 at 2:00 p.m. GMT / 9:00 a.m. ET / 6:00 a.m. PT in London, United Kingdom. A live webcast of the presentation will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days.